MYELODYSPLASTIC SYNDROMES (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROMES (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for MDS patients: targeted drug trial enters final phase
Disease control Recruiting nowThis study is testing two different drugs, ivosidenib and azacitidine, for adults with a type of blood cancer called myelodysplastic syndromes (MDS) who have a specific genetic change (IDH1 mutation) and have not yet received standard treatment. Participants will be randomly assi…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive blood cancers
Disease control Recruiting nowThis early-phase study is testing the safety of a new personalized cell therapy called CART123 for adults with advanced blood cancers that have returned or not responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target cancer,…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for toughest blood cancers: scientists tweak transplant drugs to fight disease and spare patients
Disease control Recruiting nowThis study aims to improve outcomes for patients with high-risk blood cancers who receive a stem cell transplant from a partially matched donor. Researchers are testing a modified combination of two drugs (bendamustine and cyclophosphamide) given after the transplant. The goal is…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for High-Risk transplant patients
Disease control Recruiting nowThis early study is testing if a drug called Darzalex Faspro can safely lower harmful antibodies in patients with blood cancers. Lowering these antibodies may allow patients who are currently ineligible to receive a potentially life-saving stem cell transplant from a donor. The s…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: EARLY_PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Supercharged cord blood cells target tough blood cancers
Disease control Recruiting nowThis study is testing a new cell therapy for patients whose blood cancers have returned or not responded to standard treatments. Researchers are giving patients specially engineered immune cells, called NK cells, which come from donated cord blood. The goal is to see if these mod…
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Extended safety watch for blood disorder drug
Disease control Recruiting nowThis study aims to understand the long-term safety of the drug luspatercept in people with certain blood disorders. It enrolls about 665 adults who have already participated in other luspatercept trials, either to continue treatment or to be monitored in long-term follow-up. The …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for tough blood cancers: experimental drug combo enters human testing
Disease control Recruiting nowThis early-stage study is testing a new drug called ICP-248, given alongside an existing drug (azacitidine), for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goals are to find a safe dose and see how well the body handles the combination. …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough blood cancers: optimized transplant trial seeks to control disease
Disease control Recruiting nowThis study is collecting information on patient outcomes after receiving a cord blood transplant using Memorial Sloan Kettering's optimized procedure. It aims to see how well this standard transplant approach works for adults with high-risk blood cancers like leukemia, lymphoma, …
Matched conditions: MYELODYSPLASTIC SYNDROMES (MDS)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC